Elagolix is an orally active, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of hormone-dependent disorders. It works by suppressing pituitary gonadotropin secretion, leading to reduced ovarian estrogen production. This mechanism helps manage moderate to severe pain associated with endometriosis. Elagolix offers a rapid onset of action and flexible dosing compared to injectable GnRH therapies. By effectively controlling estrogen levels, it improves symptoms while allowing individualized treatment under medical supervision.
Image
